Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma

February 9, 2016
Michael Lim, MD

Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.

Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma. Lim says medical professionals should be aware of the toxicities that come along with these checkpoint inhibitors, as well as be able to recognize the first signs of toxicities.